ITM Isotopen Technologien München AG

68 articles about ITM Isotopen Technologien München AG

• ITM Obtains Manufacturing License in the U.S.

  2/1/2024

  ITM Isotope Technologies Munich SE announced that the company has obtained a wholesale license issued by the New Jersey Department of Health in order to operate as a virtual manufacturer.

• ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program

  1/30/2024

  ITM Isotope Technologies Munich SE and Alpha-9 Oncology announced the signature of a global master clinical supply agreement to support the development of Alpha-9’s Radiopharmaceutical Therapy pipeline candidates for the treatment of cancer.

• ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board

  1/16/2024

  ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced the appointment of Dr. Mark Harfensteller to its Executive Board.

• ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site

  1/4/2024

  ITM Isotope Technologies Munich SE announced the receipt of the Radioactive Material Handling License for the company’s NOVA facility, the world’s largest Lutetium-177 production site.

• ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics

  10/24/2023

  ITM Isotope Technologies Munich SE reported on its participation at the 3rdInternational Centers for Precision Oncology Forum for Theranostics in Precision Oncology which took place in Garching near Munich, Germany, from October 12-13, 2023.

• ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

  10/18/2023

  ITM Isotope Technologies Munich SE and Canadian Nuclear Laboratories, which manages and operates the national laboratory at Chalk River, Ontario on behalf of Atomic Energy of Canada Limited, announced the launch of Actineer™ Inc., a new joint venture company between CNL and ITM for the industrial scale production of Actinium-225.

• ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023

  6/15/2023

  ITM Isotope Technologies Munich SE announced that it will host a multidisciplinary symposium titled, “Investing in the Future of Theranostics: Aligning Supply to Clinical Need,” at the Society of Nuclear Medicine and Molecular Imaging Therapeutics Conference, held from June 24-27 in Chicago, Illinois, USA.

• ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer

  6/13/2023

  ITM Isotope Technologies Munich SE announced the opening of its new production facility for therapeutic radionuclides in Neufahrn near Munich, Germany in the presence of Minister of State, Dr. Florian Herrmann and other high-ranking guests.

• ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities

  6/5/2023

  ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced an equity investment round of €255 million led by Temasek with participation from BlackRock Alternatives1,Qatar Investment Authority, Nextech2, ATHOS and Carbyne.

• ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

  4/27/2023

  ITM Isotope Technologies Munich SE announced that it has entered into a co-development and exclusive license agreement with the Paul Scherrer Institute, a leading Swiss research institute in the natural and engineering sciences, for the implementation of upscaled manufacturing of a novel therapeutic radionuclide, terbium-161.

• ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey

  4/17/2023

  ITM Isotope Technologies Munich SE, a leading radiopharmaceutical theranostics company, announced that the company has opened its U.S. headquarters in Princeton, New Jersey and appointed Roger Estafanos as U.S. General Manager.

• ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma

  3/13/2023

  ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster announced the start of a Phase I clinical trial with ITM’s drug candidate ITM-31, a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma.

• ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that CEO Steffen Schuster and CFO Dr. Klaus Maleck will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.

• ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)

  10/27/2022

  ITM Isotope Technologies Munich SE announced that the U.S. Food and Drug Administration has granted the company Fast Track designation for ITM-11, an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors.

• ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177

  10/24/2022

  An international collaboration between Bruce Power, Isogen and ITM Isotope Technologies Munich SE, announced the commencement of commercial production of lutetium-177.

• Isotope Production System begins commercial production of cancer-fighting lutetium-177

  10/24/2022

  An international collaboration between Bruce Power, Isogen and ITM Isotope Technologies Munich SE, announced the commencement of commercial production of lutetium-177.

• ITM Multiplies Production Capacity for its n.c.a. Lutetium-177

  10/13/2022

  ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced the successful completion of a new production line for the medical radioisotope non-carrier-added lutetium-177 at its production facility IAZ in Garching near Munich.

• ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network

  9/8/2022

  ITM Isotope Technologies Munich SE announced the signing of a global cooperation framework agreement to support the development and use of targeted radiopharmaceuticals for cancer diagnostics and treatment.

• ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022

  9/6/2022

  ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that a scientific poster on the design of its second phase III clinical trial, COMPOSE, in advanced neuroendocrine tumors will be presented at the upcoming ESMO Congress from September 9-13, 2022, in Paris.

• ITM Acquires a New Platform for the Development of Next-Generation Theranostics

  8/18/2022

  ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that it has signed an agreement to acquire Positron Precision GmbH, a company developing a technology platform for positron emission tomography tracers and various radiotherapeutic candidates.